 CAMBRIDGE, Mass., April 28, 2022 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial results and provide a corporate update on Thursday, May 5, 2022. Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. ET. 